Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Denosumab
DRUG: Zoledronic acid
DRUG: Placebo to Denosumab
DRUG: Standard Chemotherapy
DRUG: Placebo to Zoledronic Acid

Sponsor

Amgen